Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis
用户cZRVgnb2IzVs
25天前
40
10
已完结
1. 系统已在2025-11-17 15:05:10对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://pubmed.ncbi.nlm.nih.gov/23884486
其他信息:
PMID: 23884486
作者: Stuart Maddin; John Quiring; Lynne Bulger; Stuart Maddin; Stuart Maddin; ...
摘要: Background: Itraconazole, approved for treatment of toenail fungal infection onychomycosis, provides antifungal activity at a dosage requiring once-daily (QD) administration of 2 100-mg capsules for 12 weeks. Utilizing the Meltrex® technology delivery system, a novel 200-mg formulation of itraconazole was developed delivering the same dosage as 2 capsules in a single tablet.
